PSTK and hepatocellular carcinoma: Notably, punicalin, a hepatitis B virus (HBV) treatment agent, was identified as a potential PSTK inhibitor that showed synergistic efficacy when combined with Sorafenib in vitro and in vivo HCC treatments (Chen et al. 2022).